Modality
Degrader
MOA
HPK1i
Target
KRASG12C
Pathway
Epigenetic
LGSCeliacRSV
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Jun 2028
Phase 1Current
NCT04349865
590 pts·LGS
2018-07→2028-06·Not yet recruiting
590 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-062.2y awayPh2 Data· LGS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Not yet…
Catalysts
Ph2 Data
2028-06-06 · 2.2y away
LGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04349865 | Phase 1/2 | LGS | Not yet recr... | 590 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 |